Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system

Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system

Objective: To assess the feasibility of clinical pharmacist-led CYP2C19 genotype-guided P2Y12 inhibitor antiplatelet drug therapy recommendations to cardiologists in an outpatient cardiology practice. Methods: This was a prospective, open-labeled, single-arm study conducted in an integrated healt...

Full description

Bibliographic Details
Main Authors: Johnson SG, Shaw PB, Delate T, Kurz DL, Gregg D, Darnell JC, Aquilante CL
Format: Article
Language:English
Published: Centro de Investigaciones y Publicaciones Farmaceuticas 2017-06-01
Series:Pharmacy Practice
Subjects:
Pharmacogenetics
Genetic Testing
Pharmacists
Patient Acceptance of Health Care
Platelet Aggregation Inhibitors
Acute Coronary Syndrome
Cytochrome P-450 CYP2C19
United States
Online Access:https://www.pharmacypractice.org/journal/index.php/pp/article/view/946/514

Internet

https://www.pharmacypractice.org/journal/index.php/pp/article/view/946/514

Similar Items